Pages that link to "Q36809014"
Jump to navigation
Jump to search
The following pages link to Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions (Q36809014):
Displaying 50 items.
- Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies (Q21131216) (← links)
- Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review (Q26782025) (← links)
- In vitro and in vivo modifications of recombinant and human IgG antibodies (Q26859713) (← links)
- Improving the efficacy of antibody-based cancer therapies (Q28208361) (← links)
- Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines (Q30428210) (← links)
- Growth of Viridans streptococci on human serum alpha1-acid glycoprotein (Q30732375) (← links)
- LC-MS/MS peptide mapping with automated data processing for routine profiling of N-glycans in immunoglobulins (Q30784999) (← links)
- Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity (Q30835165) (← links)
- Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity (Q31214737) (← links)
- Evidence for mannosidase activities in Streptococcus oralis when grown on glycoproteins as carbohydrate source (Q31962995) (← links)
- Improvements to in-Line Desalting of Oligosaccharides Separated by High-pH Anion Exchange Chromatography with Pulsed Amperometric Detection (Q32115700) (← links)
- Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule (Q34067815) (← links)
- Analysis of recombinat glycoproteins by mass spectrometry (Q34167592) (← links)
- Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines (Q34323394) (← links)
- Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies (Q34574834) (← links)
- Advances in animal cell recombinant protein production: GS-NS0 expression system (Q34878044) (← links)
- Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development (Q35105725) (← links)
- Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid (Q35873009) (← links)
- Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody (Q36216376) (← links)
- Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells (Q36254504) (← links)
- Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins. (Q36601827) (← links)
- Antibody therapeutics: isotype and glycoform selection (Q36922260) (← links)
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies (Q37364355) (← links)
- Glycosylation as a strategy to improve antibody-based therapeutics (Q37402407) (← links)
- Engineering mammalian cells in bioprocessing - current achievements and future perspectives (Q37730868) (← links)
- The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs (Q37854420) (← links)
- Modulation of antibody effector function (Q37860624) (← links)
- Protein Glycosylation Control in Mammalian Cell Culture: Past Precedents and Contemporary Prospects (Q37947967) (← links)
- Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond (Q37998314) (← links)
- IgG-Fc glycoengineering in non-mammalian expression hosts (Q38013479) (← links)
- Expression of recombinant antibodies (Q38126016) (← links)
- Glycosylation: impact, control and improvement during therapeutic protein production. (Q38126913) (← links)
- The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells. (Q38348746) (← links)
- Diversity in host clone performance within a Chinese hamster ovary cell line (Q38881563) (← links)
- Impact of cell culture on recombinant monoclonal antibody product heterogeneity (Q38907094) (← links)
- Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO (Q39439938) (← links)
- Characterization of the proteases involved in the N‐terminal clipping of glucagon‐like‐peptide‐1‐antibody fusion proteins (Q39863082) (← links)
- Overview of protein expression by mammalian cells (Q39989577) (← links)
- Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants (Q40011916) (← links)
- Getting the glycosylation right: implications for the biotechnology industry (Q41176922) (← links)
- The use of serum-free medium for the production of functionally active humanised monoclonal antibody from NS0 mouse myeloma cells engineered using glutamine synthetase as a selectable marker (Q41382402) (← links)
- Gene therapy for rheumatoid arthritis. Theoretical considerations. (Q41702950) (← links)
- Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy (Q42660162) (← links)
- Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells (Q43547015) (← links)
- Identification of multiple sources of charge heterogeneity in a recombinant antibody. (Q43555101) (← links)
- Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells (Q43728275) (← links)
- In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure (Q46102748) (← links)
- High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. (Q46117208) (← links)
- Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. (Q47732599) (← links)
- Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. (Q47766012) (← links)